This clinical trial is focused on studying a liver condition called non-alcoholic steatohepatitis (NASH). NASH is a type of liver disease that occurs when fat builds up in the liver, causing inflammation and damage. The study is investigating the effects of two medications, NNC0194-0499 and Semaglutide, which are being tested to see if they can help improve liver health in people with NASH. The medications are given as injections under the skin, and the study will compare their effects to a placebo.

The purpose of the study is to determine if the combination of NNC0194-0499 and Semaglutide can improve liver fibrosis, which is the scarring of liver tissue, in people with NASH. Participants in the study will receive weekly injections for a period of 52 weeks. The study will monitor changes in liver health, including improvements in liver fibrosis and the resolution of steatohepatitis, which is the inflammation of the liver due to fat accumulation.

Throughout the study, participants will be closely monitored to assess any changes in their liver condition and overall health. The study aims to provide valuable information on whether these medications can be an effective treatment option for people with NASH, potentially leading to better management of this liver disease. The trial is designed to ensure the safety and well-being of all participants while gathering important data on the effectiveness of the treatment.